Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.78 |
| ▸ | RAB9A | P51151 | 2/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 3/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | FAAH | O00519 | 3/20 | 0.60 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA2 | P00918 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4301466 | 0.94 | ALDH1A1 (0.79) | ALDH1A1RAB9AKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL11145852 | 0.94 | ALDH1A1 (0.88) | ALDH1A1RAB9AKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL14595036 | 0.88 | ALDH1A1 (0.78) | ALDH1A1RAB9AKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL12082422 | 0.88 | ALDH1A1 (1.00) | ALDH1A1RAB9AMAPTSMN1; SMN2NLRP3 | |
| SCHEMBL22218524 | 0.85 | ALDH1A1 (0.74) | ALDH1A1RAB9AKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL1574772 | 0.85 | ALDH1A1 (0.61) | ALDH1A1RAB9AKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL10244988 | 0.84 | ALDH1A1 (0.72) | ALDH1A1RAB9AKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL19231557 | 0.84 | ALDH1A1 (0.72) | ALDH1A1RAB9AKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL10282298 | 0.84 | ALDH1A1 (0.72) | ALDH1A1RAB9AKDM4EMAPTSMN1; SMN2 | |
| SCHEMBL4301473 | 0.84 | KDM4E (0.59) | ALDH1A1RAB9AKDM4EMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3331864-B1 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2021-11-03 | — | — | EP | disclosed |
| CN-108137518-B | 1,3, 4-oxadiazole derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same | 株式会社钟根堂 | 2021-08-31 | — | — | CN | disclosed |
| US-10717716-B2 | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2020-07-21 | — | — | US | disclosed |
| US-10717716-B2 | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2020-07-21 | — | — | US | disclosed |
| EP-3124482-B1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO LTD (CN) | 2019-09-11 | — | — | EP | disclosed |
| EP-3331864-A2 | 1,3,4-OXADIAZOLE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | Chong Kun Dang Pharmaceutical Corp. (KR) | 2018-06-13 | — | — | EP | disclosed |
| US-9730944-B2 | Antiviral activity of novel bicyclic heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2017-08-15 | — | — | US | disclosed |
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-06-22 | — | — | US | disclosed |
| US-9573966-B2 | Anti-cancer activity of novel bicyclic heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2017-02-21 | — | — | US | disclosed |
| EP-3124482-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-02-01 | — | — | EP | disclosed |
| EP-2405973-B1 | THIAZOLOPYRIMIDINE MODULATORS AS IMMUNOSUPPRESSIVE AGENTS | UNIV LEUVEN KATH (BE) | 2015-04-22 | — | — | EP | disclosed |
| US-20150038494-A1 | Thiazolopyrimidine Modulators as Immunosuppressive Agents | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2015-02-05 | — | — | US | disclosed |
| US-8901132-B2 | Thiazolopyrimidine modulators as immunosuppressive agents | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2014-12-02 | — | — | US | disclosed |
| US-20140088088-A1 | ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2014-03-27 | — | — | US | disclosed |
| US-20130190297-A1 | Antiviral Activity of Novel Bicyclic Heterocycles | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) | 2013-07-25 | — | — | US | disclosed |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | PTC THERAPEUTICS, INC. (US) | 2010-12-02 | — | — | US | disclosed |
| US-20090118303-A1 | SEROTONIN 5-HT3 RECEPTOR AGONIST | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2009-05-07 | — | — | US | disclosed |
| US-7485646-B2 | Serotonin 5-HT3 receptor agonist | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2009-02-03 | — | — | US | disclosed |
| US-20070265277-A1 | Serotonin 5-Ht3 Receptor Agonist | RESEARCH FOUNDATION ITSUU LABORATORY (JP) | 2007-11-15 | — | — | US | disclosed |
| EP-1798227-A1 | SEROTONIN 5-HT3 RECEPTOR AGONIST | Research Foundation Itsuu Laboratory (JP) | 2007-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150038494-A1 | Thiazolopyrimidine Modulators as Immunosuppressive Agents | TPMT, STAT6, IL4 | ALDH1A1 517/4885RAB9A 1604/4885KDM4E 1646/4885 |
| US-20130190297-A1 | Antiviral Activity of Novel Bicyclic Heterocycles | HAVCR2, RNASE1, RNASEH1 | ALDH1A1 548/4885RAB9A 697/4885KDM4E 3714/4885 |
| US-20140088088-A1 | ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | CCNA1, CCND3, CCND1 | ALDH1A1 441/4885RAB9A 686/4885KDM4E 1541/4885 |
| US-20170174703-A1 | QUINOLINE DERIVATIVES AS SMO INHIBITORS | SMO, GLI1, SHH | ALDH1A1 892/4885RAB9A 241/4885KDM4E 415/4885 |
| US-20100305100-A1 | METHODS FOR TREATING HEPATITIS C | HAVCR2, EIF2AK2, MAVS | ALDH1A1 1497/4885RAB9A 2829/4885KDM4E 4020/4885 |
| US-20090118303-A1 | SEROTONIN 5-HT3 RECEPTOR AGONIST | HTR3A, HTR7, HTR1A | ALDH1A1 2805/4885RAB9A 849/4885KDM4E 3740/4885 |
| US-20070265277-A1 | Serotonin 5-Ht3 Receptor Agonist | HTR3A, HTR7, HTR1A | ALDH1A1 2805/4885RAB9A 849/4885KDM4E 3740/4885 |
| US-10717716-B2 | 1,3,4-oxadiazole derivative compounds as histone deacetylase 6 inhibitor, and the pharmaceutical composition comprising the same | HDAC1, HDAC5, HDAC2 | ALDH1A1 152/4885RAB9A 3739/4885KDM4E 1285/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.